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Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis 
(UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly associated with a potential risk of tuberculosis 
(TB). Active TB is a critical complication that makes it difficult to treat patients who require anti-TNF for the treatment of UC refractory 
to conventional therapy. Based on the clinical guidelines, patients with inflammatory bowel disease (IBD) are strongly recommended 
to screen for latent TB before anti-TNF administration. Considering the possibility of active or reactivated TB related to anti-TNF therapy, 
all patients with IBD should be monitored closely for TB during anti-TNF therapy, irrespective of the screening results for latent TB. 
In particular, the risk of anti-TNF-related multidrug-resistant TB (MDR-TB) in patients with IBD has not been elucidated. This paper 
reports the first case of disseminated MDR-TB that developed in a UC patient receiving infliximab despite the negative evaluation 
for latent TB screening. (Korean J Gastroenterol 2019;74:168-174)
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INTRODUCTION
Infliximab is a chimeric IgG monoclonal antibody that blocks 
tumor necrosis factor-alpha (TNF-α). Anti-TNF, including in-
fliximab, adalimumab, and golimumab, is effective in the treat-
ment of patients with ulcerative colitis (UC) refractory to con-
ventional treatment, such as corticosteroids and 5-amino-
salicylic acid. On the other hand, anti-TNF therapy is strongly 
associated with the potential risk of tuberculosis (TB). Because 
TNF-α plays an important role in regulating the immune re-
actions and anti-TNF can reduce the number of chemokine 
secretions in response to mycobacteria infections, patients 
receiving infliximab therapy have an increased risk of a re-
activation of latent TB. Therefore, patients with inflammatory 
bowel disease (IBD) should be screened for latent TB before 
starting anti-TNF therapy according to the clinical guidelines.1 
Latent TB is diagnosed by a prior history of anti-TB medication 
and contact with active TB patients, chest X-ray, tuberculin 
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Fig. 1. Colonoscopy exams showed (A, B) mild erythema, edema, and
exudate with inflammatory pseudopolyps were noted from the 
cecum to the ascending colon, and (C, D) multiple whitish scars were
found from the sigmoid colon to the rectum.
skin test (TST), and/or interferon-gamma release assay (IGRA). 
All patients with IBD diagnosed with a latent TB should be 
treated with anti-TB medication before the initiation of anti-TNF 
therapy.2 On the other hand, the negative results for latent 
TB screening before anti-TNF therapy do not exclude the risk 
of active or reactivated TB in IBD patients on anti-TNF 
therapy.1,3 All patients receiving anti-TNF therapy for the treat-
ment of IBD ought to be monitored closely for complicated 
TB, regardless of the negative evaluation for latent TB screen-
ing before starting anti-TNF therapy.
The lung is most common infected organ of TB, but ex-
trapulmonary TB, such as lymphadenitis, urinary tract infection, 
osteoarthritis, meningitis, and intestinal TB, comprises 20% 
of TB cases worldwide.4 Disseminated TB is defined as the 
presence of TB that infects two or more noncontiguous organs. 
Multidrug-resistant TB (MDR-TB) is defined as the presence 
of infection caused by strains of Mycobacterium tuberculosis 
(M. tuberculosis) that are resistant to both isoniazid and ri-
fampicin, which are the most potent agents for the treatment 
of TB. While the overall incidence of TB has declined, the 
incidence of MDR-TB increased from 3.8 to 5.9 cases per 
100,000 person-years from 2000 to 2013.5 A literature review 
did not reveal any case of MDR-TB-related to anti-TNF therapy 
in patients with IBD. This paper reports the first case of dis-
seminated MDR-TB that developed in a young female patient 
receiving infliximab for active UC refractory to conventional 
therapy, despite the negative evaluation for latent TB screening.
CASE REPORT
A 27-year-old woman, who had presented with abdominal 
pain, diarrhea, and hematochezia 9 months earlier, was diag-
nosed with UC at an outside hospital. She had never smoked, 
and her mean alcohol intake per week was 50 g. She had 
no underlying conditions and denied any family history of IBD 
and TB. She started intravenous hydrocortisone with mesala-
zine (Asacol®; Janssen Biotech, Horsham, PA, USA, 1.2 g per 
day) for induction therapy.
On the other hand, she did not enter remission after the 
induction therapy with steroids and mesalazine for UC. She 
was tested for latent TB screening considering infliximab ad-
ministration for severe UC refractory to steroids. She denied 
a history of TB infection or anti-TB medications, as well as 
the possibility of exposure to any patient with known or sus-
pected active TB. No evidence of latent or active TB was pres-
ent based on QuantiFERON Gold test (QFT-G) and chest X-ray 
at the outside hospital. She had been treated with infliximab 
(Remicade®; Janssen Biotech, Horsham, PA, USA) 5 mg/kg 
intravenously twice with a 2-week interval and the dosage 
of mesalazine was increased to 3.2 g per day. Her symptoms 
improved after infliximab therapy, but she was referred to the 
Seoul National University Hospital because of her preference.
In terms of the UC Mayo subscore, her stool frequency was 
once or twice more than normal and rectal bleeding was ob-
served one point at the initial evaluation. The clinical disease 
activity according to Truelove and Witt’s criteria was moderate. 
The laboratory findings were as follows: white blood cell counts, 
8,860/μL; hemoglobin, 8.0 g/dL; platelet counts, 569,000/μL; 
CRP, 0.60 mg/dL; erythrocyte sedimentation rate, 50 mm/hr; 
and fecal calprotectin, 215 μg/g. Her liver function tests and 
estimated glomerular filtration rate were normal. The sero-
logical markers of hepatitis B and C, anti-neutrophil cytoplas-
mic antibody titer, and anti-saccharomyces cerevisiae anti-
body were all negative. The results of IGRA (QFT-G) and chest 
X-ray were also negative. On the follow-up colonoscopy exami-
nation, mild focal erythema, and edema with inflammatory 
pseudopolyps were detected from the cecum to the ascending 
colon with multifocal fibrotic scars from the sigmoid colon 
to the rectum, suggesting mucosal healing with a Mayo endo-
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Fig. 2. Computed tomography of the chest, abdomen and pelvis showed (A) a large volume of ascites with diffuse peritoneal thickening (arrows),
which are consistent with tuberculous peritonitis, and (B) enlarged lymph nodes in the right upper and lower paratracheal area (arrows).
scopic subscore of one point (Fig. 1). Infliximab with mesala-
zine therapy was continued based on the good therapeutic 
response.
After 6 months of starting infliximab therapy, she devel-
oped progressive flu-like symptoms, including high fever, chill-
ing sense, and generalized myalgia. She also had a dry cough, 
abdominal distension, and dyspepsia. On the other hand, she 
denied bloody diarrhea and the average bowel movement was 
once a day. Upon hospitalization, her vital signs were as fol-
lows: a body temperature of 37.5℃, blood pressure of 140/94 
mmHg, heart rate of 107/min, and respiratory rate of 18/min. 
No abnormal findings were observed on the physical examina-
tion except for abdominal distension with positive shifting dull-
ness and mild tenderness around the lower abdomen. The 
laboratory results were as follows: white blood cell counts, 
5,040/μL; hemoglobin, 9.7 g/dL; platelet counts, 402,000/μL; 
CRP, 11.80 mg/dL; and erythrocyte sedimentation rate, 77 mm/hr. 
CT of the chest, abdomen, and pelvis revealed enlarged lymph 
nodes in the right paratracheal and supraclavicular area, and 
a large volume of ascites with diffuse peritoneal thickening 
that was compatible with TB peritonitis accompanied by lym-
phadenitis (Fig. 2). The examination for ascites revealed a 
low serum ascites albumin gradient with a lympho-dominant 
profile. The ascitic adenosine deaminase (ADA) level was 
154 IU/L (normal range, 5.3-17.8 IU/L). The results of the as-
citic acid-fast bacilli (AFB) smear and culture, and TB and 
non-tuberculous mycobacteria PCR were all negative. The 
re-test IGRA was also negative. Bronchoscopy and endobron-
chial ultrasound-guided fine needle biopsy were performed 
from the right paratracheal lymph node to confirm the pres-
ence of TB lymphadenitis. No abnormal findings suggesting 
endobronchial TB were noted on the bronchoscopic evaluation. 
The histology examination of the lymph node biopsy speci-
mens revealed chronic granuloma with multinucleated giant 
cells that suggested the possibility of TB lymphadenitis 
(Fig. 3). The AFB culture of the lymph node was positive for 
M. tuberculosis and the Xpert MTB/RIF (Cepheid, Sunnyvale, 
CA, USA) assay was also positive for M. tuberculosis resistant 
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Fig. 4. Clinical course. She experienced disseminated multidrug-resistant tuberculosis involved in the lung, peritoneal cavity, and multiple 
lymph nodes 27 weeks after the initiation of infliximab for the treatment of ulcerative colitis, despite the negative results for latent tuberculosis
screening. UC, ulcerative colitis; MDR-TB, multidrug-resistant tuberculosis; W, week; Km, Kanamycin; Lfx, levofloxacin; Pto, prothionamide; 
Cs, cycloserine; Lzd, linezolid.
Fig. 3. Acid-fast bacilli (AFB) stain of a paratracheal lymph node 
biopsy specimen showed granulomatous inflammation with 
multinucleated giant cells. AFB were not detected in the specimen
(AFB, ×400).
to rifampin. In addition, the AFB culture of the sputum sam-
ples was also positive for M. tuberculosis on the broth 
medium. Infliximab therapy was discontinued due to the de-
velopment of complicated TB.
Because M. tuberculosis resistant to rifampin is more likely 
to have a concomitant resistance to isoniazid,6 she received 
a combination of anti-TB drugs with intramuscular kanamycin 
1 g every 24 hours, oral levofloxacin 750 mg per day, prothio-
namide 1,500 mg per day, cycloserine 250 mg three times 
per day, and pyridoxine 50 mg three times per day for suspi-
cious disseminated MDR-TB based on the consultation with 
a TB specialist. Her symptoms were relieved gradually, and 
she was discharged after 13 days of hospitalization. After 
4 weeks of the anti-TB drugs, however, she was re-hospitalized 
for cramping abdominal pain and vomiting developed. 
Abdominal radiography and ultrasound showed gaseous dis-
tention of the small bowel, suggesting paralytic ileus asso-
ciated with MDR-TB peritonitis. Intravenous agents, including 
linezolid 600 mg every 24 hours, meropenem 1 g every 
8 hours, and oral clavulanic acid 625 mg every 8 hours were 
added considering the insufficient efficacy of the previous reg-
imens for MDR-TB peritonitis. The patient was discharged with 
an improvement of her symptoms on hospital day 26. All 
symptoms related to MDR-TB subsided 9 weeks after starting 
anti-TB medication.
Approximately 3 months after the initiation of anti-TB ther-
apy, the results of the drug sensitivity test (DST) for M. tuber-
culosis from the sputum specimen on the broth medium were 
as follows: resistance to all first-line agents for TB, including 
isoniazid, rifampicin, ethambutol, and pyrazinamide, as well 
as streptomycin and quinolone. Based on the results of DST, 
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the regimens were switched to intramuscular kanamycin 
1 g five times per week, oral prothionamide 250 mg three 
times per day, cycloserine 250 mg three times per day, line-
zolid 300 mg once per day, and delamanid 100 mg twice 
per day. Kanamycin was discontinued due to an adverse ef-
fect of paresthesia 9 months after the initiation of 
administration.
The follow-up sputum AFB smear and culture results were 
all negative 3 weeks ago after starting the anti-TB medications. 
She had quiescent TB during 12 months of anti-TB medication. 
She also maintained the clinical remission of UC using mesala-
zine (Pentasa® SR; Ferring AS, Vanlese, Denmark, 2 g twice 
per day) with probiotics (Saccharomyces boulardii, Bioflor®; 
Kuhnil Pharmaco. Co., Seoul, Korea, 250 mg 3 times per day) 
after discontinuing the infliximab therapy. Fig. 4 summarizes 
her clinical course.
DISCUSSION
The 27-year-old female patient with steroid-refractory UC 
experienced disseminated MDR-TB involving the lung, peri-
toneal cavity, and multiple lymph nodes 27 weeks after the 
initiation of infliximab, despite the negative results for latent 
TB screening. She improved after being administered multiple 
therapeutic regimens for MDR-TB with the discontinuation of 
infliximab. Moreover, she did not experience clinical relapse 
within 12 months after the discontinuation of infliximab. A 
literature review revealed IBD patients on anti-TNF therapy 
to have a higher risk of extrapulmonary or disseminated TB 
than the general population.2 In a Groupe d’Etude Thérapeutique 
des Affections Inflammatoires du tube Digestif (GETAID) co-
hort study, 91% of cases of anti-TNF-associated TB involved 
at least one extrapulmonary site.3 In a recent Korean multi-
center observational study, 25 cases (2.9%) of TB developed 
among 873 patients with IBD receiving anti-TNF agents.7 
Among them, three cases (12%) were pulmonary MDR-TB, but 
there was no case of disseminated TB resistant to both iso-
niazid and rifampicin. In the present case, however, primary 
MDR-TB developed in both lung and multiple extrapulmonary 
organs of a patient with UC receiving infliximab. Similar to 
this case, some patients with IBD can experience the develop-
ment of anti-TNF-related TB, even though their results for la-
tent TB screening were negative before starting anti-TNF. The 
mean interval between the first exposure of infliximab and 
the diagnosis of TB ranges from 8 to 19 weeks.8,9 
Approximately 50% of individuals infected with TB develop ac-
tive TB within 1 to 2 years after the infection, but the remain-
ing half can develop at any time in their lifetime.
One hypothesis of the complicated TB related to infliximab 
despite the negative evaluation for latent TB is that the 
screening results using chest X-ray and IGRA test were a false 
negative. IGRA includes QFT-G, QuantiFERON®-TB Gold In Tube 
(Cellestis limited, Carnegie Victoria, Australia), and T-SPOT®.TB 
(Oxford Immunotec Ltd., Abingdon, UK). The sensitivity of 
QFT-G for latent TB was 75% (95% CI, 66-82%).10 Immune- 
mediated diseases using immunosuppressive agents are 
closely related to the decreased sensitivity of QFT-G for latent 
TB. In lymphocyte-deficient patients, the sensitivity of QFT-G 
for latent TB was only 39% (95% CI, 21-57%).11 IGRA demon-
strates immune sensitization by detecting a cell-mediated im-
mune response by stimulation with mycobacterial antigens. 
Recent steroid prescription can induce indeterminate results 
of IGRA. Therefore, IBD patients receiving immunosuppressive 
agents can produce inaccurate results of IGRA for latent TB. 
The screening results for latent TB using IGRA should be in-
terpreted carefully in IBD patients, particularly those taking 
immunosuppressive agents, such as steroids.
The other hypothesis is that the patient without latent TB 
comes in contact with patients with active TB during anti-TNF 
therapy. Patients with infectious TB can spread infectious 
droplets to others even with light contact, such as talking for 
5 minutes or coughing once. Approximately 3.3% of household 
contacts of MDR-TB and 4.8% of household contact of 
drug-susceptible TB resulted in the development of active 
TB.12 South Korea, in which the incidence of active TB was 
77 per 100,000 persons in 2016, has a high burden of TB 
despite the national and full-scale efforts to eradicate TB 
infections. The incidence of latent TB among healthcare work-
ers was at least 3% per year,13 which makes it difficult to 
control TB infections.
TB peritonitis is an unusual manifestation of TB that occurs 
through hematogenous spread from the lung and the re-
activation of a latent TB in the peritoneum. The diagnosis 
of TB peritonitis remains a challenge for clinicians because 
of the difficulty in diagnosing this condition. The gold standard 
for the diagnosis of TB peritonitis is an ascitic fluid or peri-
toneal biopsy culture positive for M. tuberculosis. On the other 
hand, it might take more than 4 weeks with a modest sensi-
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tivity of 66-83% in as much as 1 L of ascitic fluid.14 The sensi-
tivity of an AFB culture of laparoscopic biopsy for TB peritonitis 
is 93%, but the biopsy is invasive and expensive. Therefore, 
alternative non-invasive diagnostic tools, including AFB stain-
ing, PCR and ADA level in the ascitic fluid, and IGRA, are 
used for the early detection of TB peritonitis. Nevertheless, 
the diagnostic sensitivity of an ascitic fluid AFB smear is only 
2.9% and PCR for M. tuberculosis reveals a low sensitivity 
of 48% in smear-negative ascites.15 An ascitic fluid ADA activ-
ity of more than 30 IU/L is accepted as the cut-off level ex-
pected to provide the highest diagnostic yields for TB peri-
tonitis, with a sensitivity and specificity of more than 90%.14 
On the other hand, the high ADA in the ascites does not al-
ways mean TB peritonitis. Instead of the microbiological diag-
nosis, radiology images, such as abdominal ultrasound and 
CT, may be helpful in diagnosing TB peritonitis as well as 
in evaluating the involvement of other extrapulmonary organs.
TB lymphadenitis is the most common manifestation of ex-
trapulmonary TB. A definite diagnosis of TB lymphadenitis can 
be made by the demonstration of M. tuberculosis through 
an AFB culture or PCR of the affected lymph node. An exci-
sional biopsy is the most sensitive but most invasive diag-
nostic test. On the other hand, needle aspiration and biopsy 
are safer and more practical than an excisional biopsy, espe-
cially when a surgical approach is unavailable. In this case, 
bronchoscopic lymph node biopsy was performed using an 
Xpert MTB/RIF assay to define the presence of TB lymphade-
nitis in the mediastinum. The Xpert assay is a validated diag-
nostic tool for extrapulmonary TB regardless of the micro-
biological confirmation.16 IGRA is also a valuable diagnostic 
tool for both extrapulmonary and pulmonary TB. The sensi-
tivity for the diagnosis of extrapulmonary TB was 72% (95% 
CI, 65-79%) for QFT-G or QuantiFERON Gold in-tube test.17 
On the other hand, further investigations will be needed to 
evaluate the utility of IGRA depending on the sites of TB 
involvement.
In this case, M. tuberculosis was detected from the sputum 
AFB culture despite normal chest X-ray findings. All suspected 
extrapulmonary TB patients are required to evaluate the possi-
bility of concomitant lung involvement because pulmonary TB 
is also present in approximately 10-50% of extrapulmonary 
TB patients.18 Some patients with extrapulmonary TB can 
have a positive sputum culture for M. tuberculosis despite 
the normal chest X-ray. In a retrospective study, there was 
no significant difference in the positivity of a sputum culture 
for M. tuberculosis from extrapulmonary TB patients between 
abnormal and normal chest X-ray findings.19
Rifampin resistance was confirmed by an Xpert assay in 
this case. In terms of the treatment of rifampicin-resistant 
TB, clinicians should consider the administration of sec-
ond-line anti-TB medications for MDR-TB because approx-
imately 90% of rifampin-resistant specimens also showed iso-
niazid resistance. The regimen for the MDR-TB treatment 
should be individualized based on the patients’ DST results, 
and at least four susceptible drugs should be included. The 
duration of MDR-TB treatment can also be tailored. A combi-
nation of oral and injectable agents for 9 to 12 months is 
recommended in patients with MDR-TB.20
In a retrospective study from India, which has high ende-
micity of TB, UC patients with TB on anti-TNF therapy showed 
good responses to anti-TB medication and remained in the 
remission state for the next 24 months after discontinuing 
the anti-TNF therapy,8 which is consistent with the present 
case. Therefore, the clinical outcomes of UC in patients who 
develop complicated TB-related to anti-TNF might be promis-
ing, even if the anti-TNF is discontinued. Patients with compli-
cated TB should not take anti-TNF before the complicated TB 
is cured. On the other hand, resuming anti-TNF after the com-
pletion of anti-TNF medications can be considered because 
approximately 50% restarted anti-TNF therapy after the com-
pletion of anti-TB drugs. On the other hand, none experienced 
a relapse of TB during the follow-up periods in the GETAID 
cohort study of participants diagnosed with TB after the first 
anti-TNF therapy.3
One limitation of this case was that TST was not performed 
for the latent TB screening. On the other hand, the specificity 
of TST for the detection of latent TB is attenuated by Bacillus 
Calmette-Guérin (BCG) vaccination, which is strongly recom-
mended for all infants according to the national immunization 
program of South Korea. Therefore, the utility of TST for latent 
TB screening appears to be low.
This paper reports the first case of a patient with UC who 
was diagnosed with primary disseminated MDR-TB related to 
infliximab therapy despite the negative evaluation for latent 
TB before the initiation of infliximab. IBD patients receiving 
anti-TNF therapy should be monitored carefully in a region 
with a high prevalence of TB, irrespective of the screening 
result for latent TB before anti-TNF therapy. The possibility 
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of primary MDR-TB should be considered during the diagnosis 
of complicated TB related to anti-TNF therapy based on the 
increasing trend in the incidence of MDR-TB worldwide.
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